Baricitinib Associated With Significant Improvement in RA

Share this content:
Baricitinib Associated With Significant Improvement in RA
Baricitinib Associated With Significant Improvement in RA

MONDAY, Feb. 20, 2017 (HealthDay News) -- For patients with rheumatoid arthritis who have had an inadequate response to methotrexate, baricitinib is associated with significant clinical improvements, compared to either placebo or adalimumab, according to a study published in the Feb. 16 issue of the New England Journal of Medicine.

Peter C. Taylor, M.D., Ph.D., from University of Oxford in the United Kingdom, and colleagues conducted a 52-week, phase 3, double-blind controlled trial, in which 1,307 patients with active rheumatoid arthritis who were receiving background therapy with methotrexate were randomly assigned to one of three regimens in a 3:3:2 ratio: placebo (switched to baricitinib after 24 weeks), 4 mg of baricitinib once daily, or 40 mg of adalimumab (an anti-tumor necrosis factor α monoclonal antibody) every other week.

Using the American College of Rheumatology criteria, the researchers found that more patients had a 20 percent improvement at week 12 with baricitinib versus placebo (70 versus 40 percent; P < 0.001) or adalimumab (70 versus 61 percent; P = 0.014). All major secondary objectives, including inhibition of radiographic progression of joint damage at week 24, were met with baricitinib versus placebo (mean change from baseline, 0.41 versus 0.90; P < 0.001). Compared with placebo, adverse events (including infections) were more frequent through week 24 with baricitinib and adalimumab. Cancers were reported in five patients (two taking baricitinib and three taking placebo). Reductions in neutrophil counts and increases in levels of creatinine and low-density lipoprotein cholesterol were noted with baricitinib.

"In patients with rheumatoid arthritis who had had an inadequate response to methotrexate, baricitinib was associated with significant clinical improvements as compared with placebo and adalimumab," the authors write.

The study was supported by Eli Lilly, the manufacturer of baricitinib, and Incyte.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Recent Decline in Prescription Opioid Use Among U.S. Teens

Recent Decline in Prescription Opioid Use Among U.S. ...

Lifetime prevalence of use peaked in 1989, 2002, and remained stable until decline in 2013 to 2015

Treatment Seeking Low Among Teens With Eating Disorders

Treatment Seeking Low Among Teens With Eating Disorders

Those with counter-stereotypic presentation even less likely to seek treatment

Optical Clearing Agent Ups No. of Laser Passes in Tattoo Removal

Optical Clearing Agent Ups No. of Laser Passes ...

Findings based on number of laser passes during a five-minute tattoo removal session

is free, fast, and customized just for you!

Already a member?

Sign In Now »